Back to search

Article

Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL

2015-12-03

Abstract excerpt

Abstract Recent studies have demonstrated promising preclinical efficacy for the combination of ibrutinib with venetoclax (formerly ABT-199/GDC-0199) in CLL; however, the biology underlying how ibrutinib enhances the sensitivity of CLL cells to BCL-2 antagonism by venetoclax has heretofore remained obscure. Our group previously developed BH3 profiling, a functional assay that determines the proximity of a cell to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
18201b0e-1822-596d-9fbe-00e2a26ef958
DOI
10.1182/blood.v126.23.490.490
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLLDOI 10.1182/blood.v126.23.490.490
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismSemantic proximity
Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclaxSemantic proximity
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteinsSemantic proximity
Early cytokine-driven adaptation of survival pathways in lymphoid cells during targeted therapiesSemantic proximity
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignanciesSemantic proximity
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic ChemotherapySemantic proximity
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia.Semantic proximity
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell LymphomasSemantic proximity
Mitochondrial apoptosis and BH3 mimeticsSemantic proximity
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSemantic proximity
Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.Semantic proximity
Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.Semantic proximity
Select a neighboring publication to make it the new centre.